Remedy Robotics
Develops AI-enabled robotic systems for endovascular intervention.
The record
- Vertical
- Devices & Robotics
- Sub-segment
- Endovascular robotics
- Product type
- Device
- Stage
- Series B
- Headquarters
- San Francisco, CA, United States
- Region
- North America
What they do
Remedy Robotics is developing the N1 System, an AI-enabled endovascular robotic platform and software suite for on-site, remote and potential autonomous intervention. On 16 November 2026 it announced a $62 million Series B led by DCVC, supporting clinical trials, work toward FDA approval and prototype deployment with clinical partners. The company explicitly states that N1 remains under development and is not available for sale or clinical use in any jurisdiction. Dr. David Bell is CEO and co-founder.
Investors
- DCVC
- UC Investments
- Skip Capital
- Hostplus
- Build Collective
- Blackbird
- Divergent Capital
- KdT Ventures
History and progression
How Remedy Robotics got here, step by step.
16 November 2026
$62 million Series B
DCVC led a $62 million Series B to support N1 clinical trials, development and work toward FDA approval.
Recent news
16 November 2026
Remedy Robotics announcement16 November 2026
David Bell, CEO and Co-founder16 November 2026
Remedy Robotics Series B details
Related companies